pharmaphorum

OCTOBER 13, 2020

UK biotech e-therapeutics has a new CEO, with executive chairman and former Silence Therapeutics chief Ali Mortazavi chosen to spearhead the next stage in the company’s development into gene silencing and other areas. The company has considerably more cash than at the start of the year – on 31 July it had £15.1

Gene Silencing 98

Gene Silencing Gene RNA Genome 98

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. Automated systems have become a prominent feature throughout drug discovery, helping scientists save time and assisting in reproducible experiments for more verifiable results.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

DECEMBER 23, 2020

The results also suggest further uses for the drug in early disease and more revenues to come from one of the company’s biggest success stories from the last decade. Unlike conventional cancer drugs Vitravki can be used in tumours with this mutation regardless of whether they are in the body.

Marketing 92

Marketing Gene Silencing Gene Drugs 92

Delveinsight

AUGUST 6, 2020

The present hATTR treatment market constitutes compounds that stabilize the TTR tetramers, a TTR-directed small interfering RNA, and a TTR-directed antisense oligonucleotide, along with supportive therapies. Gene-silencing Therapies. hATTR market : In The Pipeline. hATTR market : In The Pipeline.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52